The effect of Telbivudine on virus serology and liver biopsy in HBV carriers

Fu MaoYing; Gu XueFeng; Chang Feng; Zhang Wei; Ji XueLiang

Issue 5

May 2010

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2010 > 26(5): 515-516+526

PDF( 1222 KB)

The effect of Telbivudine on virus serology and liver biopsy in HBV carriers

Published Date: 2010-05-20

Abstract

Abstract

Objective To observe the changes on virus serology and liver biopsy among HBV carriers treated with Telbivu-dine.Methods 42 HBV carriers were divided randomly into treatment group and control group.Telbivudine 100 mg/d was given orally for the treatment group for more than one year.Oxymatrine capsule was given orally for the control group for six months.Liver biopsy and HBVM, HBVDNA and liver fibrosis indexes were tested during the treatment.Results After six months of treatment the improvement of liver biopsy and HBVM, HBVDNA, and liver fibrosis indexes improved significant-ly in the treatment group than the control group (P < 0.05) , and the index of hepatic inflammation activity in the treatment group decreased from 7.8 ± 3.8 to 4.5 ± 4.2 (t = 7.358, P < 0.01) .Conclusion Telbivudine therapy has a significant short-term curative effect on HBV carriers.
- hepatitis B,
- carrier state,
- hepatitis B antibodies,
- hepatitis B antigens,
- Telbivudine

FullText(HTML)

References(8)

References

[1]Hann HW.Active antiviral therapy for chronic hepatitis B and hepa-tocellular carcinoma[J].Minerva Gastroenterol Dietol, 2008, 54 (1) ∶19-30.

[2]Yamamoto T, Kondo S, Sugawara A, et al.Case of fulminant hepat-ic failure in an elderly asymptomatic HBV carrier without proximatecause[J].Nippon Shokakibyo Gakkai Zasshi, 2008, 105 (12) ∶1781-1786.

[3]Lok AS.HBV treatment stragegie should based on publisheddata[J].AGA perspectives, 2006, 2 (1) ∶4-12.

[4]中华医学会.慢性乙型肝炎防治指南[J].中华肝脏病杂志, 2005, 13 (12) ∶881-891.

[5]Pan XC, Yang F, Chen M, et al.The effect of telbivudine on pe-ripheral blood CD4+CD25+regulatory T cells and its significancein patients with chronic hepatitis B[J].Zhonghua Gan Zang Bing ZaZhi, 2008, 16 (12) ∶885-888.

[6]Chu CM, Liaw YF.Hepatitis B virus-related cirrhosis:natural his-tory and treatment[J].Semin Liver Dis, 2006, 26 (2) ∶142-152.

[7]Hui CK, Leung N, Shek WH, et al.Changes in liver histology as a“surrogate”end point of antiviral therapy for chronic HBV can pre-dict progression to liver complications[J].J Clin Gastroenterol, 2008, 42 (5) ∶533-538.

[8]Hoofnagle JH, Doo E, Ling TJ, et al.Management of hepatitis B:summary of a clinical reseach workshop[J].Hepatology, 2007, 45 (4) ∶1056-1075.

Relative Articles

[1]	Wang RongQi, Nan YueMin. Neutropenia caused by telbivudine in chronic hepatitis B patients: a report of one case[J]. Journal of Clinical Hepatology, 2015, 31(2): 273-274. doi: 10.3969/j.issn.1001-5256.2015.02.031
[2]	Dong XiaoPing. Therapeutic effect of telbivudine combined with Fuzheng Huayu tablets in treatment of liver fibrosis in chronic hepatitis B: a report of 60 cases[J]. Journal of Clinical Hepatology, 2013, 29(9): 689-691. doi: 10.3969/j.issn.1001-5256.2013.09.014
[3]	Jiang XiuNong, Fan LingYan, Li DeZhou, Wan Jiong, Ye JingJing. Clinical trial of telbivudine in the treatment of chronic hepatitis B in patients during the third trimester of pregnancy[J]. Journal of Clinical Hepatology, 2013, 29(2): 101-103.
[4]	Xie Rong, Jiang JianNing, Su MingHua, Liu ZhiHong, Zhong ShaoHua, He LiXia, Liang YanXiu, Hu JiaGuang, Huang XiaoHong, Guo WenWen, Fu WuDao, Zhu MeiQin, Wang BaoJian. Efficacy and safety of initial telbivudine treatment in chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2012, 28(6): 422-424+427.
[5]	Chen XiaoQin, Yao ZhanCheng, Wu LiPing, Chen MingChun, Zhang YanPing, Wu Yi. Clinical study on telbivudine in preventing mother-to-infant HBV transmission during the late pregnancy[J]. Journal of Clinical Hepatology, 2011, 27(12): 1282-1284.
[6]	Yao QinJiang, Ma WeiGuo. Therapeutic efficacy of telbivudine in hepatitis B e antigen positive chronic hepatitis B patients with high baseline alanine aminotransferase levels[J]. Journal of Clinical Hepatology, 2011, 27(6): 614-616.
[7]	Song LiWen, Zhao GuiMing, Cao WuKui, Lu ChengZhen. Meta analysis of the comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(9): 955-961.
[8]	Zhao WenLi, Wang BaoChun, Huang Fei. Therapeutic effects of 48-week telbivudine treatment in patients with cirrhosis caused by HBV[J]. Journal of Clinical Hepatology, 2011, 27(8): 840-843.
[9]	Wang HaiYan, Wang Yu, Peng XiaoMing, Liu Ya. Recent advancement of telbivudine in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(12): 1320-1322+1326.
[10]	Zhan GuoQing, Tan HuaBing, Zhang WeiWei, Li RuGui, Xie XingRong, Hu Bo. The factors predicting the efficacy of telbivudine in the treatment of HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(6): 608-610.
[11]	Jin QingLong, Wang ZhongFeng, Yan HongQing, Niu JunQi. The study of the change in creatine kinase in patients with chronic hepatitis B during the antiviral treatment with Telbivudine and Lamivudine[J]. Journal of Clinical Hepatology, 2011, 27(2): 143-144+156.
[12]	Hua JianPing, Ma GuiFeng, Li ChunHui, Li JunMei, Bing YuZhi, Zhang QiuYin. The effect of Telbivudine therapy in patients with decompensated cirrhosis caused by HBV[J]. Journal of Clinical Hepatology, 2010, 26(6): 602-604+607.
[13]	Zhu LongDong, Yuan Hong, Chen Lin. Pathological and clinical analysis of chronic asymptomatic HBV carriers[J]. Journal of Clinical Hepatology, 2010, 26(6): 633-634+637.
[14]	Wu HangYuan, You DeHong. The efficacy of Telbivudine therapy on decompensated hepatitis B cirrhosis documentation[J]. Journal of Clinical Hepatology, 2010, 26(6): 605-607.
[15]	Mo MuLong, Gan ChuLin, Zhong DaMing, Zhou Su, Xu RiAn, Liang ZhuShi. The relationship between serum hepatitis B virus markers and traditional Chinese medicine type of syndrome[J]. Journal of Clinical Hepatology, 2010, 26(5): 513-514.
[16]	Huang Jing, Lin Hua, Xi Li, Liu Min. Analysis of serum markers of hepatitis B virus in 77286 cases by chemiluminescence method [J]. Journal of Clinical Hepatology, 2010, 26(3): 324-325.
[17]	Zhou XiuYun, Chen YingHua. Study on the relationship between liver histology and serological indexes in 50 cases of hepatitis B virus carriers [J]. Journal of Clinical Hepatology, 2010, 26(5): 508-509.
[18]	Zhang WeiWei, Yuan XueHua, Tan HuaBing, Zhan GuoQing, Li RuGui, Du WeiXing. Therapeutic Efficacy of telbivudine with phentolamine on patients with chronic severe hepatits B[J]. Journal of Clinical Hepatology, 2009, 25(6): 418-419.
[19]	Li Zhi, Yan HongMei, Xue FaXuan, Wang Tong, Liang Qun, Xu Huan, Li ZhangChun. Short-term clinical effect of telbivudine in the treatment chronic hepatitis B[J]. Journal of Clinical Hepatology, 2009, 25(6): 420-421+426.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (4151) PDF downloads(796)

The effect of Telbivudine on virus serology and liver biopsy in HBV carriers

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

The effect of Telbivudine on virus serology and liver biopsy in HBV carriers

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content